Hematologic Malignancies

Hematologic Malignancies

An inhibitor of FLT3 known as ASP2215 showed good clinical activity in FLT3-mutated patients with relapsed or refractory acute myeloid leukemia (AML).

A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.

We discuss some of the anticipated multiple myeloma trials with Sagar Lonial, MD, ahead of the 2015 American Society of Clinical Oncology Annual Meeting.

Patients with acute myeloid leukemia who had a DNMT3A mutation had poorer disease prognosis, according to an analysis of patients aged 60 years or younger.

Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.

Women who were treated for Hodgkin lymphoma during childhood and adolescence had similar rates of post-treatment parenthood as that of the general population.

The addition of elotuzumab to lenalidomide and dexamethasone improved progression-free survival and overall response rate in relapsed multiple myeloma patients.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.